TCRX
TScan Pauses Key Trials, Shifts Focus to Solid Tumors
TScan paused enrollment in the Phase 3 ALLOHA-2 study due to insufficient capital; the company is reorganizing to focus resources on developing two in vivo-engineered TCR-T candidates for solid tumors. Stock reaction: PURSUANT TO RULE 11a-3 UNDER THE ACT: THIS IS AN ANNOUNCEMENT NOT REQUIRE FILING U…
TCRX
TScan reports positive Phase 1 data for TSC-101 in heme malignancy study
TScan Therapeutics announced positive initial data from Cohort C of the ALLOHA Phase 1 study, with 11 of 14 patients achieving complete donor chimerism within three weeks and 93% showing clinical response. The company remains on track to enroll its first patient in the Phase 3 ALLOHA-2 study this mo…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.